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Abstract 
Introduction: Chronic kidney disease (CKD) is recognized as a health care problem of increasing 
importance. Following the discovery of renal progenitors, the investigation of new therapeutic 
approaches to promote the kidney regenerative capacity has received increasing research attention.  
Areas covered: The authors discuss the current knowledge of glomerular regeneration by renal 
progenitors and the modulation of their behavior through chemical and biological agents. The 
regenerative capacity of renal progenitors after injury must be regulated in order to prevent an 
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inefficient or excessive response that could lead to a failed attempt to replace lost podocytes. In 
addition, they discuss the most relevant pathways involved in tubular repair and how these could be 
modulated in order to obtain renal regeneration rather than progression of a fibrotic maladaptive 
response.  
Expert opinion: Further studies are needed to establish the existence of tubular progenitors and 
their role in driving the tubular response after injury. Modulation of the endogenous renal 
regenerative capacity is a new approach in the treatment of kidney diseases. Research efforts that 
concentrate on the potential regenerative capacity of the kidney can be advantageous when the 
experimental results are translated into clinical practice and may open the way to new therapeutic 
strategies for CKD. 
 
Key words: chronic renal failure, AKI, progression, CKD, tubule, glomerulus 
 
1. Introduction 
Chronic kidney disease (CKD) is recognized as a health care problem of increasing importance and 
for this reason, in 2002, guidelines were developed by independent, international, multidisciplinary 
work groups with clinical and technical expertise to find a uniform definition and classification for 
CKD [1]. The introduction of these guidelines showed that CKD is far more frequent than 
previously appreciated, affecting > 10% of the world’s population [2, 3]. In addition, acute kidney 
injury (AKI) is a global public health concern impacting ∼13.3 million patients per year [4] that 
associates with high morbidity and about 1.7 million deaths per year. Patients affect by an AKI 
episode risk developing CKD and end-stage renal disease (ESRD), or exacerbate a pre-existing 
condition of CKD accelerating the progression to ESRD [5-6]. For these reasons, finding new 
therapies for kidney diseases is mandatory. The definition of the mammal kidney as an organ with 
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limited capacity to regenerate, due to its intricate architecture and its rich diversity of cell types [7-
8], has been recently called into question. Emerging evidence have shown that the kidney contains a 
population of renal progenitors that have the potential to regenerate different portions of the damage 
nephron [9] (See explanatory box). In this review, we describe and discuss some very recent and 
noteworthy results on the modulation of renal regeneration and we suggest how new discoveries can 
be applied in order to eventually develop new therapies. 
2. GLOMERULAR REGENERATION: EVIDENCE AND MECHANISMS 
The first clinical evidence of glomerular regeneration was described in a study by Fioretto et al. 18 
years ago. They observed regression of renal disease with glomerular and tubular architecture 
remodeling in patients affected by diabetic nephropathy who underwent pancreas transplantation 
after 10 years of normoglycemia [10, 11]. Further evidences showed the renoprotective effect of 
renin-angiotensin-aldosterone system inhibitors (RAAS-I), either angiotensin-converting-enzyme 
inhibitors (ACE-I) or angiotensin receptor blockers (ARB). Patients with a continued RAAS-I 
therapy exhibited a stabilization and even amelioration of kidney function, that could delay or 
prevent the need of renal replacement therapies [12-15]. In various animal models of chronic 
proteinuric nephropathies, including aging, the treatment with ACE-I, ARB or their combination, as 
well as other therapeutic interventions not only avoided progressive renal damage but also fostered 
regression of glomerulosclerosis [9, 15-19]. In addition, through 3D reconstruction of the glomeruli 
using serial kidney sections was demonstrated that regeneration of segmental sclerosis and 
remodeling of the glomerular architecture can occur unless the glomeruli are not affected by global 
sclerosis [15]. In agreement, a previous experimental study described a correlation between the 
extension of glomerusclerosis and kidney function decline on one side and the degree of podocyte 
depletion following renal damage on the other [19]. Different possible mechanisms have been 
provided to understand the effects of renoprotective therapies, including the extracellular matrix 
deposition in sclerotic lesions and the cell survival promotion of the glomerular capillary tuft and 
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Bowman’s capsule [20]. Accordingly, in a rat model of advanced nephropathy ACE-I treatment 
reduced mesangial cell proliferation, remodeled glomerular endothelial architecture, and increased 
glomerular podocyte number [20]. Because podocytes have limited capacity to divide and they 
cannot restore glomerular architecture through cell division, the existence of an intrarenal 
glomerular progenitor was mostly likely. In recent years, strong evidence has suggested that Renal 
Progenitors Cells (RPCs) may exist in humans, and represent a potential source for podocyte 
replacement through proliferation and differentiation [21-23]. At the urinary pole of the Bowman’s 
capsule a subset of parietal epithelial cells (PEC) with features of RPCs were identified. These cells 
co-express two progenitor markers, CD133, a trans-membrane glycoprotein and marker of several 
types of adult stem cells and CD24, a surface molecule expressed by renal embryonic cells. Isolated 
RPCs were characterized by the expression of transcription factors characteristic of different types 
of stem cells, and the presence of functional properties characteristic of stem cells, that are self-
renewal, high clonogenic efficiency and multidifferentiation potential [22, 24-26]. In the adult 
kidney, RPCs are distributed in a hierarchical sequence within the Bowman’s capsule from 
immature progenitor cells, located at the urinary pole, to cells committed to become podocytes at 
the vascular pole [25]. When injected into a mouse model of Focal Segmental Glomerulosclerosis 
(FSGS), human RPCs engrafted, replaceed lost podocytes and improved proteinuria, suggesting that 
RPCs can differentiate into podocytes and promote podocyte regeneration. Using an inducible 
transgenic mouse model where PEC were tagged Appel et al. showed that these cells can 
differentiate into podocytes during adolescence, acquiring their structural and phenotypic 
characteristics [27]. Nevertheless, following studies using lineage tracing methods produced 
different results, showing that parietal epithelial cells do not migrate onto the glomerular tuft to 
replenish podocytes in adult mice in physiologic conditions and in models of glomerular 
hypertrophy [28]. However, Wanner et al. using a diphtheria toxin–mediated acute podocyte loss 
model demonstrated the regenerative capacity of podocytes, observing that newly generated ones 
replaced 38% of lost podocytes [29]. Recently, Eng DG et al. using an inducible transgenic mouse 
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model affected with cytotoxic anti-podocyte antibody-induced FSGS provided a new further 
evidence that PEC were able to regenerate podocytes [30]. In this model PEC, which were 
permanently labeled after induction, migrated from Bowman's capsule to the glomerular tuft and 
acquired podocyte features to replace lost ones [30]. However, when podocyte loss is severe, 
regeneration does not occur while hyperplastic cellular lesions as those seen in crescentic 
glomerulonephritis or collapsing glomerulopathy were observed in association with the production 
of extracellular matrix proteins. In particular, it was demonstrated that most cells forming these 
lesions express the RPC markers CD24 and CD133 with or without co-expression of podocyte 
markers. These results suggested that the generation of these lesions might be the consequence of an 
abnormal proliferative and migratory response of RPCs at various stage of their differentiation 
condition toward podocytes that failed to replace the injured podocytes [31-35]. 
Very recently, Lasagni et al. proposed a definite explanation about these two conflicting behaviours 
of RPCs, suggesting that the regenerative response of RPCs to podocyte injury influences the 
outcome of CKD [36]. Using an inducible transgenic mouse model of FSGS where podocytes were 
labeled, they observed that, either the remission of disease associated with proteinuria reduction or 
the progression of disease associated with persistent proteinuria were explained by the amount of 
regenerated podocytes. New podocytes descended not from preexisting podocytes but from 
unknown podocyte progenitors. To establish the origin of new podocytes, they generated an 
inducible transgenic mouse model of FSGS for RPCs lineage tracing using the regulatory region of 
the transcription factor Pax2, a molecule that plays important roles in kidney development and is 
specifically co-expressed with CD133 in human RPCs. This mouse model allowed authors to trace 
single Pax2 labelled cells and their progeny, demonstrating definitely that lost podocytes were 
replaced from Pax2 labelled cells, suggesting that these cells exhibit a renal progenitor phenotype in 
mice. Of note, the replacement of podocytes from Pax2 labelled cells was observed mainly within 
glomeruli of mice with proteinuria remission. An average of about 30 % of the lost podocytes were 
replaced by Pax2 labelled cells that acquired structural and phenotypic characteristic of fully 
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differentiated podocytes. By contrast, the analysis of kidneys in mice with persistent proteinuria 
exhibited a higher percentage of glomeruli with sclerosis and no new podocytes were observed in 
comparison to mice with proteinuria remission. In these mice, the percentage of Pax2+ cell-derived 
podocytes was irrelevant suggesting that the progression or remission of glomerular disorder 
depends on the balance between an efficient and dysfunctional differentiation of Pax2+ RPCs in 
fully podocytes. This study provides a definite answer to the role of RPCs as the source for 
podocyte regeneration after injury [36]. 
Recently, Pippin et al. described another putative source of renal progenitor cells such as cells of 
renine lineage (CoRL) located in the juxtaglomerular compartment (JGC) [37]. The authors, by 
using four different transgenic mouse models of FSGS, traced the fate of renin expressing cells and 
observed that CoRL had regenerative capacity and were able to replace both glomerular epithelial 
cells, PEC and podocytes [37]. Other studies suggested that CoRL are pluripotent progenitors also 
for mesangial cells, vascular smooth muscle cells and pericytes [37, 38]. Taken together, these data 
suggest that CoRL may represent upstream mesenchymal progenitors that generate parietal 
epithelial cells that, in turn, regenerate podocytes (Table 1). 
2.1 Targets and pathways that regulate RPC regenerative capacity 
Growing evidence suggests that the regenerative capacity of RPCs after injury must be strictly 
regulated to prevent an inefficient or excessive response that can lead to failed attempt to replace 
lost podocyte [32]. Several studies are now starting to identify mechanisms that regulate RPC 
growth and differentiation (Figure 1, Table 1). 
2.1.1. SDF-1/CXCR4: The chemokine Stromal cell-derived factor (SDF-1) or CXCL12 and its own 
receptor CXCR4 are important regulators of stem and progenitor systems all over the body [39]. 
Several evidence suggest that this pathway is also a critical mediator of RPC function within the 
kidney in homeostatic as well as inflammatory conditions [39]. An inflammatory environment is 
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known to induce an increase of CXCR4 expression on progenitor cells in renal proliferative 
disorders. Moreover, macrophages may activate podocytes to produce the CXCR4 ligand, SDF-1, 
that mediates progenitor migration and proliferation leading to hyperplasia [40]. In vitro and in vivo 
studies demonstrated that the CXCL12 inhibition increased podocyte number and enhanced RPC 
differentiation toward the podocyte lineage, thus improving regeneration [40]. In addition, the dual 
antagonism of the chemokine ligand Monocyte Chemotactic Protein-1 (MCP-1) or CCL2 and 
CXCL12 showed synergistic effects preventing the glomerulosclerosis in diabetic nephropathy 
adding up the protective effect on CCL2-mediated glomerular leukocyte recruitment with that on 
CXCL12-mediated loss of podocytes [40]. These findings promote CXCL12 blockade as a novel 
strategy to prevent more efficiently crescentic lesions and glomerulosclerosis and to foster the 
regenerative capacity of RPCs (Figure 1).  
2.1.2 Notch and Wnt/β-catenin: The signaling pathways that are involved in the control of RPC 
growth and differentiation are only partially known; among them, the Notch and Wnt/β-catenin 
pathways are well known. Notch signaling controls the balance between podocyte loss and renewal 
provided by RPCs and influences the outcome of glomerular injury in a mouse model of FSGS [41]. 
In vitro experiments demonstrated that Notch activation in RPCs promotes their entry into the S-
phase of the cell cycle; on the contrary, down-regulation of Notch signaling is essential for RPC 
differentiation into podocytes. Accordingly, blocking the Notch signaling in the regenerative phases 
in a mouse model of Adriamycin nephropathy induced a worsening of proteinuria and 
glomerulosclerosis [41, 42]. Persistent Notch activation induced podocytes to override the G2/M 
checkpoint, resulting in death by mitotic catastrophe [41, 43]. Furthermore, in a transgenic mouse 
model of collapsing FSGS, the inhibition of Notch signaling reduced RPC hyperplasia but 
worsened podocyte loss and proteinuria [42]. Recent data obtained in mice demonstrated that the 
Wnt/β-catenin pathway is essential for correct cell fate decision of PEC during the late stages of 
nephrogenesis [44]. Indeed, conditional β-catenin knockout mice displied abnormal kidneys and 
had reduced renal function. Their kidney appeared hypoplastic, most of the glomeruli had aberrant 
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morphology with underdeveloped capillary tufts and well-differentiated podocytes replaced PEC in 
the Bowman’s capsule [44] (Figure 1). 
2.1.3 Glycogen synthase kinases 3-α and -β (GSK3s): In a recent study, Lasagni et al. identified 
the glycogen synthase kinases 3-α and -β (GSK3s) inhibitor BIO as a strong promoter of RPCs 
differentiation toward podocyte, both in vitro and in vivo [36]. In vitro treatment with BIO of human 
RPCs enhanced their differentiation towards podocytes up-regulating nephrin expression, in 
comparison to exposure only to the differentiating molecule retinoic acid (RA). In particular, the 
authors observed that the effect of this compound is to synchronize cells in G0/G1 phase of the cell 
cycle and enhance RA binding to its specific response elements. This evidence was further 
confirmed by in vivo experiments. In mouse model of FSGS performed in inducible transgenic 
mice, where podocytes were tagged, the administration of BIO induced proteinuria remission with 
increased number of newly generated podocytes. Moreover, to verify if the presence of new 
podocyte after the treatment of BIO was due to an increase of RPCs differentiation toward the 
podocyte lineage the mouse model of FSGS was also performed in inducible Pax2 transgenic mice 
where RPCs were tagged. Accordingly, the BIO treatment enhanced the number of RPCs (Pax2+ 
cells) that acquired structural and phenotypic markers of fully differentiated podocytes as WT1 and 
Synaptopodin [36]. These observations demonstrate that the course of CKD can be shifted from 
progression to remission by acting pharmacologically on the RPCs response to injury (Figure 1). 
2.1.4 Retinoic acid (RA): RA is a strong inducer of RPC differentiation toward the podocyte 
lineage in vitro [45]. It induces upregulation of podocyte-specific genes, like nephrin, by binding to 
RARE in the promoter and inducing transcription [26]. Interestingly, the RPC capacity to 
differentiate toward podocytes in vitro can be impaired by exposure to albumin, which binds RA 
with high affinity. In mouse model of FSGS, blocking the endogenous RA synthesis increased 
albuminuria, glomerular injury and mortality [45]. These data suggest that RA is essential for a 
correct differentiation of RPCs into podocyte and that the presence of even a small amount of 
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albumin within the Bowman’s space reduces RA bioavailability and can be detrimental for a 
suitable regenerative process to occur [45]. These results provide a biological rationale for the well-
established renoprotective role of RAAS-I. The effects of these proteinuria-lowering drugs are 
directed on the RPCs and neutralizing the sequestering activity of albumin restored their 
regenerative response [45] (Figure 1). 
2.1.5 Micro-RNAs: Strong evidence showed that micro-RNAs (miRNA), that are small noncoding 
RNA that regulate gene expression at the post-transcriptional level, play a key role in stem cell self-
renewal and differentiation. In particular, miR-1915 and miR-1225-5p are expressed in adult RPCs 
and have been identified as regulators of stemness and differentiation capacity through the tight 
modulation of CD133, Pax2 and TLR2 [46]. Moreover, the Oct4/miR145 balance is involved in 
stemness maintenance during hypoxia [47]. A reduction during the hypoxia of miR-145, 
constitutively expressed by CD133+ cells from papilla, mediated by the activation of Oct4, possibly 
permitted cell proliferation and maintenance of progenitor phenotype. On the contrary, an 
upregulation of miR-145, concomitantly with the Oct4 reduction, was observed during the 
differentiation allowing cell maturation and the proliferation to stop.  
Other miRNA families are described as important players in modulating podocyte physiology and 
diseases pathogenesis. The miR-30 family protects podocytes from apoptosis and cytoskeletal 
injury by inhibiting Notch1 and p53 [48]. Moreover, in a mice model of FSGS miR-193a and miR-
206 over-expression led to a cascade of podocyte-destabilizing events, starting with the down-
regulation of WT1 and Synaptopodin inducing cell death [49, 50]. In addition to these studies, in a 
mouse model of nephrotoxic nephritis an inhibition of miR-193a resulted in reduced crescent 
formation and decreased proteinuria [51]. Taken together, these results suggest that miR-193a 
functions as a master switch that regulates the expression of PEC and podocyte markers in 
glomerular epithelial cells. 
 
2.2 Drugs and biological mediators that modulate RPC regenerative capacity  
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Several drugs were described that may potentially modulate RPC capacity to proliferate and 
differentiate into podocytes and may thus be used to enhance glomerular regeneration (Figure 1, 
Table 1). 
2.2.1 Renin-angiotensin-aldosterone system (RAAS): Given the well-established renoprotective 
effects of RAAS-I, some studies were performed in order to clarify if their beneficial effects are 
attributable to an enhancement of RPC differentiation into podocytes. In a rat model of glomerular 
injury, a subset of parietal epithelial cells characterized by the expression of the marker Neural cell 
adhesion molecule (NCAM) in the Bowman’s capsule was considered responsible for the regression 
of glomerular lesions [52]. Indeed, after the administration of ACE-I was observed a reduced 
proliferative response by NCAM+PEC and a reduced extension of glomerular hyperplastic lesions. 
These data demonstrated the occurrence of a normal glomerular architecture restoration that 
prevented the progression toward glomerulosclerosis [52]. One of the mechanisms through which 
ACE-I worked was the involvement of the cell cycle inibitor C/EBPδ. Indeed, ACE-I treatment in 
vitro resulted in an up-regulation of C/EBPδ expression that limited PEC proliferation. 
Accordingly, the exposure of PEC to angiotensin II reduced the expression of C/EBPδ and induced 
their proliferation. Moreover, the Angiotensin (Ang) II receptor AT1 which expression is up 
regulated in the hyperplastic lesions seems to play a key role in the mechanisms responsible for 
RPC proliferation and migration [53]. These evidences suggested a pivotal contribution of Ang 
II/AT1 pathway in abnormal RPC behavior in proliferative diseases and added another explanation 
to the renoprotective effects of ARB treatment [53]. Indeed, in patients affected by crescentic 
glomerulonephritis who underwent to ACE-I therapy was observed a total remission of glomerular 
hyperplasia associated to a reduction of RPC proliferation and a reduceced expression of AT1 
receptor [53]. 
Very recently, Lichtnekert et al. described a new effect after administration of RAAS-I that 
determined an increased podocyte number in the absence of podocyte proliferation by acting on 
CoRL [54]. Indeed, by using an inducibile transgenic mouse model of FSGS where CoRL were 
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tagged, the author observed that the administration of RAAS-I increased the proliferation in JGC, 
the migration towards the glomerulus and enhanced the plasticity of CoRL toward three different 
glomerular cell lineages (podocytes, parietal epithelial cells and mesangial cells) [54] (Figure 1). In 
addition, a recent study documented for the first time an effect of RAAS-I on the regeneration of 
kidney vasculature. After the administration of both ACE-I and Ang II/AT1 antagonist to rat model 
of progressive glomerular injury was observed an higher increased glomerular capillary volume and 
length than in control animals at the same age [55]. 
2.2.2 Steroids: The therapeutic benefit of corticosteroids in the management of glomerular diseases 
is well known, although if a direct effect on specific cell types of the glomerulus has been only 
partially understood. A recent study demonstrated that daily prednisone administration to mice with 
experimental FSGS improves the outcomes increasing podocyte number and reducing proteinuria 
and glomerulosclerosis. Of note, this effect was due to the limit of podocyte apoptosis and to the 
enhancement of number of RPCs (Pax2+ cells) that acquired markers of podocytes as WT1 and 
Synaptopodin [56] (Figure 1). 
2.2.3 Interferons: Interferons (INFs) were also reported as glomerular epithelial cells (RPC and 
podocyte) modulators in vitro and in vivo [57]. In vitro exposure of podocyte to either IFN-α or to 
IFN-β demonstrated that only IFN-β specifically alter the podocytes permeability and promote their 
loss by inducing mitotic catastrophe. On the contrary in vitro exposure of RPCs to either IFN-α or 
to IFN-β demonstrated that only IFN-α affected proliferation and migration of RPCs. Moreover, in 
vitro exposure to both IFNs impaired the differentiation of RPCs into mature podocytes. This 
evidence was further confirmed by in vivo experiments.  The injection either IFN-α or IFN-β into 
mice with Adriamycin–induced nephropathy worsened the proteinuria and the glomerular injury. In 
particular, the INFs had distinct effects. The administration of IFN-β mainly affected podocyte 
decreasing their numbers. Instead, the administration of IFN-α predominately affected PEC 
inducing their cell cycle arrest and impairing podocyte repair [57] (Figure 1). 
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2.2.4 Retinoic acid (RA): In mouse model of FSGS, the exogenous administration of RA that 
neutralize sequestering activity of albumin, allowed the regenerative response of RPCs, determining 
an increase in podocyte number and the improvement of renal function [45]. The data also showed 
that RA restores a correct differentiation of RPCs into podocyte and avoids generation of 
hyperplastic glomerular lesions and of glomerulosclerosis [45] (Figure 1). 
2.2.5 Leptin: A recent study described that the administration of leptin promotes disease regression 
resulting in near-complete reversal of both structural and functional parameters in an animal model 
of advanced diabetic nephropathy [17]. In addition, leptin replacement resulted in the restoration of 
the podocyte number/density and in the increase of WT-1 positive and proliferating PEC. These 
observations suggest that PEC may be a potential reservoir to re-establish lost podocytes and that an 
efficient differentiation of PEC into podocytes is essential for the regression of diabetic 
nephropathy that might be pharmacologically enhanced (Figure 1). 
 
3. TUBULAR REGENERATION: EVIDENCE AND MECHANISMS 
 
The kidney has a remarkable capacity for repair and regeneration, which is evidenced by apparently 
complete recovery of function despite a relevant nephron loss, occurred after AKI. The current 
pathophysiological concept explaining functional recovery from AKI is based on the high 
proliferative capacity of all tubular epithelial cells after injury via a process of dedifferentiation, cell 
division and redifferentiation to replace adjacent lost tubular cells [58, 59]. Indeed, a large body of 
evidence demonstrates that tubular regeneration is orchestrated within the tubule itself. Humphreys 
et al. used genetic fate mapping and transgenic mice to label tubular epithelial cells or tubular 
interstitium, concluding that regeneration by surviving epithelial cells was the predominant 
mechanism of repair after ischemic injury and thus, rulling out the implication of extra-tubular cells 
[60]. However, this extensive tubular regenerative capacity is in the last decade questioned because 
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epidemiological studies document that even mild AKI episodes imply a substantial risk of 
subsequent CKD [61]. Indeed, if whatever surviving tubular epithelial cell would have such a high 
capacity to proliferate and replace lost tubular cells after injury, this would not explain the reason 
why CKD is so frequent after an episode of AKI. In this regard, a recent publication by Rinkevich 
et al. observed that adult damaged kidneys could undergo tubulogenesis through clonal expansion 
of a small subset of tubular cells [62]. In this study, by using an inducible transgenic mouse model, 
driven by the specific tubular marker Actin promoter and by using the Confetti reporter the authors 
performed a clonal analysis on ischemic kidneys by analyzing tubular epithelial cells at the single 
cell level and evaluating the effective cell division. This reporter enables the expression of one out 
of four fluorescent proteins in a stochastic manner, thus allowing the examination of the individual 
behaviour of multiple cells and to visualize clonal expansion of single cells that will appear as 
continuous clusters of cells of the same color. These results supported the hypothesis about the 
presence of tubular-committed progenitors as responsible of the repair of the injured tubuli. 
Consistently, other investigators suggested the existence of a specific tubular cell subpopulation 
scattered intra tubular cells in humans with high regenerative potential and resistance to death [63-
66]. Indeed, human tubular-committed progenitors, that are scattered within the proximal tubule, 
thin descending limb and thick ascending limb of Henle’s loop, the distal convoluted tubule and the 
connecting segments, are characterized by expression of RPC markers (CD133+CD24+) [63-67] 
and by the expression of cytokeratin 7 and cytokeratin 19 in presence of low levels of tubular 
markers [63, 64]. Several studies have evidenced that these cells exhibited a flask shape with no, or 
less pronounced brush border and a unique ultra-structural charcteristics such as a condensed 
chromatin in smaller and darker nuclei compared to the surrounding cells [65, 66]. In addition, the 
expression of vimentin, claudin-1 and COL7A1 in the basal compartment of these cells confer an 
increased adherence to the basement membrane and an increased robustness; whereas a high BCL2 
expression associated with very few mitochondria confer a higher resistance to death compared to 
other tubular cells [65, 66]. Indeed, CD133+ tubular progenitors exhibited an increased resistance to 
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death in vitro in comparison to other tubular cells following exposure to potentially nephrotoxic 
agents like hemoglobin [64]. This evidence was further corroborated by Hansson et al. who 
developed an ex vivo explant culture system where the vascular clamping of human kidneys 
undergoing nephrectomy was utilized to simulate acute tubular necrosis [66-]. Although this 
procedure produced massive tubular necrosis CD133+ tubular progenitors survived, providing 
further functional evidence that these cells were more resistant to insult than bulk epithelium. In 
addition, even if in healthy human kidney CD133+ tubular progenitors represent only the 2-6% of 
all tubular cells, owned to their survival capacity they become the dominant existing population 
immediately after injury, since adjacent differentiated tubular cells preferentially die [63, 64]. This 
enrichment may explain why CD133+ tubular progenitor markers increase immediately after injury 
and why the increased prevalence of such an undifferentiated population may be wrongly 
interpreted as the result of dedifferentiation. Taken altogether, these studies suggest that tubular 
cells are heterogenous and that at least two distinct tubular populations (differentiated tubular cells 
and tubular progenitors), exhibiting different sensitivity to injury, could exist in healthy adult 
kidneys. Further studies are needed to enhance our knowledge of tubular regenerative capacity after 
injury and to define the putative existence of tubular progenitors and establish their role in response 
to injury.  
 
3.1 Targets to promote tubular regeneration 
 
Regardless of determining the actual existence of a tubular progenitor, cellular and molecular 
mechanisms of tubular repair after AKI have been extensively investigated in a variety of 
experimental models in order to identify a number of candidate therapies for AKI. The major 
challenge consists in considering the clinical relevance of these models in human AKI and how 
such models might be improved to optimize translation into successful clinical trials. Both human 
and animal studies have shown that a variety of intrinsic repair processes is activated rapidly after 
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kidney injury [60, 68] and that progression toward ESRD results directly or indirectly to 
maladaptive repair processes. Maladaptive repair occurs in the tubular, vascular, and interstitial 
compartments in response to AKI, predisposing to development of interstitial fibrosis. A reduction 
in capillary density after AKI may exacerbate renal hypoxia and thus, promote interstitial fibrosis 
[69, 70]. Paracrine signals such as the expression of profibrotic factors (Trasforming Growth 
Factor- β, TGF-β, Connective Tissue Growth Factor-B, CTGFB and Platelet-Derived Growth 
Factor B, PDGFB) produced from the local environment (tubular epithelial cells and infiltrating 
cells) synergize to expand and maintain interstitial changes [68]. More importantly, it is widely 
accepted the key role of tubular cells in favouring a pro-fibrotic response. Indeed, tubular epithelial 
cells represent a further source of profibrotic factors when they fail to proliferate and growth arrest 
in G2/M phase of cell cycle [71]. Thus, the main mediators of maladaptive processes are currently 
considered as the main targets in order to halt progression of renal damage and to foster renal 
regeneration (Figure 2). 
3.1.1 Hypoxia and oxidative stress mediators: Capillary rarefaction resulting in hypoxia [69, 70] 
and oxidative stress [72, 73] may play a major role in both developments of AKI and subsequent 
progression towards CKD. Cells are endowed with powerful defensive mechanisms against hypoxia 
and oxidative stress (hypoxia-inducible factor, HIF and nuclear factor erythroid 2-related factor 2, 
Nrf2), and these may be appropriate therapeutic targets. HIF activation before induction of AKI 
ameliorates the degree of kidney injury [74] and more importantly, pharmacologic HIF activation 
prevented the development of fibrosis after ischemia reperfusion injury (IRI) in mice, resulting in 
an improved tissue repair and in a suppression of inflammation [74]. The antifibrotic effect is not 
observed if HIF activation occurs after induction of AKI, which may actually exacerbate tissue 
injury if chronic hypoxia is already present [74]. These observations emphasize that there is a 
narrow therapeutic window of HIF activation. Similarly, exogenous vascular endothelial growth 
factor (VEGF) administered to preserve renal capillaries also has a therapeutic window only in the 
early postinjury period, whereas it fails to protect when administered several weeks after injury 
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[75]. Pharmacologic Nrf2 activation and subsequent upregulation of antioxidative genes 
ameliorated experimental bilateral ischemic AKI in mice [76] and improved aristolocholic acid-
induced AKI in mice [77]. Because persistent oxidant stress is a feature of AKI models leading to 
fibrosis, pharmacologic Nrf2 activation is theoretically a promising approach to attenuate AKI to 
CKD transition (Figure 2). 
3.1.2 Inflammatory mediators: AKI is accompanied by an inflammatory sterile response that 
contributes to tubular cell damage [68]. Macrophages are key regulators of inflammation and 
fibrosis as also demonstrated in a prospective study where the analysis of biopsies from CKD 
patients has revealed that the number of macrophages in the interstitium correlated directly with 
glomerular scarring, interstitial fibrosis, atrophic tubules, reduced capillary density, and decreased 
renal survival. Macrophages are characterized by a remarkable plasticity in responding to 
extracellular cues reflecting a heterogeneous phenotype and function of these cells. Indeed, it is 
possible to assign a phenotype to the macrophage population associated with a harmful pro-
inflammatory function (M1classically activated cells) or with a tissue reparative function (M2 
alternatively activated cells) [78]. Genetic or pharmacologic inhibition of macrophage colony-
stimulating factor 1 signaling blocked macrophage/dendritic cell proliferation decreased M2 
polarization and inhibited recovery [79]. These findings showed an important role for colony-
stimulating factor 1 mediated expansion and polarization of resident renal macrophage/dendritic 
cells in renal tubule epithelial regeneration and suggest that more myeloid cell-derived mediators 
that enhance epithelial healing should be investigated. In addition, the predominant trigger for the 
associated-AKI inflammatory response is tubular cell necrosis, because the release of intracellular 
molecules (damage-associated molecular patterns, DAMPs) from dying tubular cells elicit several 
strong immunostimulatory effects. These molecules can activate a set of pattern recognition 
receptors, such as Toll-like receptors (TLRs), on tubular epithelial cells as well as on the interstitial 
dendritic cells [80]. The subsequent innate immune response involves the transcription of numerous 
proinflammatory cytokines and chemokines, which initiate the influx of various immune cell 
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subsets into the kidney, contributing to amplification of the inflammatory response and enhancing 
immune-mediated tubular cell death. M2 macrophages produce IL-10 and growth factors like TGF-
β that have regulatory roles in tissue repair such as anti-inflammatory and profibrotic effects [80]. 
To this regard, a recent study documented for the first time a role of IL-22, which is a member of 
the IL-10 family of cytokines, demonstrating a remarkable regulatory effect in tissue repair through 
activation the proliferation of tubular epithelial cells [81]. In particular, authors demonstrated that 
TLR4 agonists released from necrotic tubular cells is a strong specific stimulus for IL-22 secretion 
from interstitial dendritic cells and macrophages. Consistently, TLR4 blockade during the early 
phase and during the healing phase suppressed IL-22 production and impaired kidney regeneration, 
demonstrating that this cytokine is a previously unknown mediator of tubular epithelial cell 
regeneration during AKI recovery phase and that renal mononuclear phagocytes can also 
orchestrate kidney regeneration beyond renal inflammation (Figure 2). 
3.1.3 Hippo and Notch signaling pathways: With advances in developmental biology, many 
signalling pathways that coordinate cell proliferation, death and differentiation are discovered. One 
important pathway is the Hippo pathway characterized by a three-step kinase cascade composed of 
Mst1/2 (mammalian sterile 20-like kinase ½), Lats1/2 (large tumour suppressor ½) and YAP (Yes-
associated protein). The latter is the Hippo pathway major downstream effector as revealed in 
studies about heart, liver and intestinal regeneration [82, 83]. A recent study demonstrated the key 
role of YAP in controlling proliferation and redifferentiation of renal tubular cells after acute IRI 
[84]. After strengthening of YAP signalling by using digitoxin as a specific agonist, promotion of 
renal tubular cell proliferation was documented, but a subsequent exacerbation of fibrosis followed 
the attempt to repair in the kidneys of IRI-induced AKI rat models. These experiments suggest that 
YAP might exhibit bidirectional functions in AKI: during repair, YAP mainly exerted beneficial 
effect on proliferation of the injured renal tubular epithelial cells, however, a constant activation of 
YAP exacerbated postinjury fibrosis and prevented the redifferentiation of dedifferentiated tubular 
cells. Consistently, others have demonstrated that YAP promote renal fibrotic process, activating 
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TGF-β signalling via retaining activated Smad2/3 in the nucleus [85]. In vivo treatment with 
verteporfin, a specific YAP inhibitor, identifies this molecule as a novel potent inhibitor of 
experimental fibrosis. Indeed, this treatment reduced renal interstitial YAP abundance together to a 
decreased nuclear Smad2/3 accumulation and a decreased expression of fibrotic markers in the 
kidney [85]. Inhibition of YAP signaling represents a novel tool that can interfere with the 
regulation of TGF-β/Smad signaling and identifies a promising new antifibrotic treatment strategy 
to halt the progression of CKD. 
The Notch signaling pathway is another highly conserved mechanism of intercellular 
communication influencing a wide variety of developmental processes of the kidney throughout 
embryogenesis and adulthood [86]. Besides these, activation of Notch pathway has been implicated 
in tissue repair in the adult kidney [86]. Indeed, kidneys after experimental AKI in mice showed 
increased expression of Notch receptors, specifically Notch1-3, of the Notch ligands (Jagged-1, 
Jagged-2, Delta-like-4) and of the Notch target genes (Hes-1, Hey2, HeyL, Sox9 and PDGFB). 
Consistent with this, activation of Notch pathway in tubular epithelial cells caused a rapid 
development of tubulointerstitial fibrosis [87]. Blockade of the Notch pathway, by using γ-secretase 
inhibitor starting at 24h and at 1-2 hrs before ischemia-reperfusion injury, involved less interstitial 
edema formation, a decreased expression of the Notch receptors (Notch3 and Notch1), its ligands 
(Delta-like-4 and Jagged-1) and PDGFB leading to a reduction of fibrosis with an amelioration of 
renal function. These data demonstrate that the severity of kidney injury can be ameliorated by 
blocking Notch activation through pharmacologic inhibition of Notch activation following AKI [88] 
(Figure 2). 
3.1.4. Cell cycle control: Recent discoveries have enhanced our understanding about the role of 
tubular cell cycle control in AKI repair. Cell cycle analysis in vivo proved to be predictive tool for 
determining the progression of kidney injury to either tubular epithelial cell proliferation and repair 
or fibrosis. After the first 24 hours of ischemic injury, tubular cells undergo apoptotic and necrotic 
cell death. In response, many of the surviving, normally quiescient proximal tubule epithelial cells 
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proliferate and enter the cell cycle in order to cover the denuded area [89]. This process appears to 
be driven by various cyclins and cyclin-dependent kinases (Cdks) Cdk4/6 and Cdk2 and fast 
synthesized checkpoint proteins such as p21 [89]. Also referred to as CDK-interacting protein 1 
(CIP1), p21 binds to and antagonizes cyclin-CDK complexes, resulting in G1 phase cell cycle 
arrest. Previous studies suggest that expression of the Cdk inhibitor p21 ameliorates the injury [90] 
and that overexpression of p21 or the use of other Cdk inhibitors can protect against cisplatin and 
ischemic cell death [91]. The cell exerts cell cycle arrest as a protective mechanism to avoid cell 
division when it is potentially damaged during stress and injury [92]. Therefore, the modulation of a 
transient expression of Cdk4/6 or Cdk2 inhibitors represents a novel strategy to improve renal repair 
and could provide protection against early tubular cell death but still allows subsequent proliferation 
in order to repopulate injured tubules. Thus, temporary G1 cell cycle arrest should reduce kidney 
damage; however, in order for cells to divide and begin the process of repair, they must enter and 
exit each phase of the cell cycle on schedule [92]. If the cells exit a phase too soon, or stay in a 
phase too long, the normal repair and recovery processes can become maladaptive [93]. Indeed, 
after a DNA damage involvement, if the cells do not re-initiate the cell cycle and remain arrested in 
G1 or G2 phase, a fibrotic phenotype can be favored, contributing to a late decline of renal function 
and providing a hypothetic pathophysiological link between AKI and CKD [71, 93, 94]. The 
association of G2/M arrest and production of profibrogenic growth factors, such as TGF-b and 
CTGF, from the tubular cells provide strong evidence that tubular cells arrested in G2/M have a 
primary role in determining the fibrotic response [71, 94]. In these conditions, the percentage of 
cells that underwent G2/M arrest correlated with the development of fibrosis [71, 94] and 
consistently, pharmacologic intervention, which increased number of tubular cells arrested in G2/M 
phase after AKI, worsened kidney fibrosis. By contrast, interventions, which enhance the movement 
through G2/M phase of cell cycle, were associated with less fibrosis and an improvement of tissue 
integrity [95, 96]. Thus, the damaged tubular epithelial cell can contribute to fibrosis process via 
paracrine mechanisms that are potentiated by a state of accelerated senescence characterized by 
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G2/M arrest and production of profibrotic factors that, in turn, acts to upregulate profibrotic 
cytokine production. The presence of DNA damage associated with severe injury, secondary to 
ischemia, aristolochic acid exposure or unilateral ureteral obstruction, is the main cause to force 
tubular epithelial cells toward G2/M arrest. Indeed, activation of the ATM/ATR pathways that is 
characterized for downstream G2/M arrest and secretion of fibrotic factors has been observed in 
rodent models and in kidney diseases in humans [94]. Taken altogether, these considerations 
suggest that the true division potential of tubular cells after injury is unknown and may be 
considerably lower than what previously thought. Interestingly, old pathology studies based on 
evaluation of the occurrence of mitoses, as the only proof of effective cell division in injured 
tubular tissue, reported that tubular division was rare [97]. This limited regenerative potential may 
better explain the high incidence of CKD observed in patients with previous AKI episodes and 
suggest that the use of pharmacologic activators that push tubular epithelial cells in the progression 
of cell cycle is theoretically a promising approach to attenuate the AKI to CKD transition (Figure 
2). 
3.1.5 Epigenetic modifications: Histone modifications, DNA methylation, and cromosomal 
conformational changes that regulate gene expression can be activated after kidney injury. Of note, 
by using zebrafish embryo as a screening tool, it was identified a new histone deacetylase inhibitor 
(HDACi), PTBA, which expanded the pool of renal progenitor cells in a proliferation-dependent 
manner [98]. Following this, an esterified analog of PTBA, 4mPTB, was identified as a molecule 
with higher efficacy than the parent compound in inducing expansion of the renal progenitor cell 
pool in zebrafish embryo [95]. Consistently, it was demonstrated, for the first time, that m4PTB 
treatment accelerated recovery and reduced postinjury fibrosis after IR-induced AKI in mice [97]. 
This finding is associated with activation of transcriptional programs involved in promoting cell 
cycle progression, a reduction in G2/M arrest, and an increase in the proportion of proliferating 
tubular epithelial cells in the G1 and S phases of the cell cycle. These results suggest that 4mPTB 
accelerates functional recovery after AKI by enhancing effective regenerative capacity of surviving 
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tubular epithelial cells. In addition, since m4PTB improves recovery from AKI when administered 
24 hours after IRI in mice, it could be a drug particularly attractive because of its efficiency when 
adminstered in patients a few days after the occurrence of the initial insult. The HDACi are already 
described as promising drugs to improve renal function reducing fibrosis in a variety of different 
rodent models of CKD [99, 100]. The underlying mechanism of this improvement is uncertain but 
several hypotheses are generated and discussed. It has been shown that epigenetic changes obtained 
with histone hyperacetylation induced by m4PTB decreases fibrosis by reprogramming interstitial 
fibroblasts [101]. However, since renal tubular cells activate inflammatory programs that drive 
interstitial fibrosis and G2/M arrest of these cells is the expression of a maladaptive repair 
mechanism that promotes postinjury fibrosis in models of severe AKI [71], we can speculate about 
the hypothetical efficacy of m4PTB in reducing postinjury fibrosis by driving renal tubular cells 
through the G2/M checkpoint. Thus, the beneficial effects of m4PTB are mediated by positive 
regulation of cell cycle-dependent processes involved in renal tubular cell regeneration rather than a 
reduction in cell injury (Figure 2). 
4. Conclusions 
Many advances have been made on the modulation of renal regeneration. In the glomerulus, it has 
been demonstrated that targeting the regenerative response of RPC, by using pharmacological 
approaches or targeting potential pathways, is able to shift from progression to remission the 
glomerular disease, In the tubule, regardless of whether that the existence of tubular progenitors and 
their role in the regenerative response is still to be clarified, cellular and molecular mechanisms of 
tubular repair have been extensively investigated in order to identify a number of potential 
pathways to be targeted. The main mediators of maladaptive processes are currently considered as 
the main targets in order to halt progression of tubular damage and to foster tubular regeneration. 
Promising results have demonstrated that fostering tubular proliferation capacity may represents the 
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critical aspect in order to obtain a shift toward tubular regeneration instead of progression of a 
maladaptive response. 
5. Expert opinion  
 
Identification of RPCs in the adult kidney was a crucial step forward in regenerative medicine, 
demonstrating that regenerative capacity of the adult kidney also exists in mammals. Targeting 
these cells by using pharmacological approaches or targeting potential pathways that, indirectly, are 
able to accelerate the regenerative response may be a near-term application of regenerative 
approaches. Experimental data have recently clarified how podocyte replacement by RPCs occurs, 
demonstrating that it could be limited or completely abolished when albumin within the Bowman’s 
space increases even slightly, as it happens in proteinuric disorders, sequestering RA, the key 
molecule for RPC differentiation toward the podocyte [45]. Accordingly, in the advanced phases of 
the disease, the endogenous regeneration of the podocytes operated by RPCs seems unable to 
correct and replace successfully a significant amount of lost podocyte, and RPCs rather chaotically 
proliferate and migrate, leading to lesion formation and subsequent sclerosis [, 45, 53]. This 
phenomenon is not ineluctable, as underlined by the occurrence of glomerular regeneration when 
protein lowering drugs such as ACEis are used, and can be even pharmacologically enhanced, 
turning failure into success [9, 20]. Indeed, the enhancement of the repair process operated by RPCs 
toward regeneration could be obtained through the delivery of further drugs [9, 20, 56] or targeting 
putative renoprotective pathways [40-42, 44, 57]. In a recent study, Lasagni et al. identified the 
glycogen synthase kinases 3-α and -β (GSK3s) inhibitor BIO as a strong promoter of RPC 
differentiation toward podocyte by promoting RA mediated effects [36]. More importantly, 
treatment with GSK3s inhibitor BIO induced proteinuria remission by enhancing RPC 
differentiation into podocytes in inducible transgenic mouse models of FSGS, demonstrating that 
the shift from progression to remission of kidney disease it is possible by modulating the 
regenerative response of RPCs is possible. However, future studies will likely identify further 
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candidate signaling pathways implicated in RPC’ maintenance, regulation and response after injury. 
On the other hand, regarding the regeneration of the tubular compartment, how much can the tubule 
regenerates and who performs regeneration after an episode of AKI is still a source of controversy. 
Further studies are necessary to increase our knowledge of the tubule regenerative capacity after 
injury, enabling us to define the putative existence of tubular progenitors and to establish their role 
in response to injury. In particular, it would be necessary to identify the mouse counterpart of 
human tubular progenitors in the adult mouse kidney by using a marker specifically expressed by 
that progenitor population. Unfortunately, a marker that specifically allows progenitors tagging in 
mouse adult kidneys remains unknown. Despite this, novel experimental strategies are needed to 
provide the effective regenerative potential of all tubular cells. In this regard, since some relevant 
pathways in the regenerative response after AKI have been identified in preclinical experimental 
models, it would be neccessary to investigate also their potential therapeutic activity. However, 
none of these has been confirmed in a successful phase III clinical trial. The difficulty to validate 
each target in specific animal models that consider comorbidities that would alter patient 
susceptibility, such as diabetes, aging, obesity, cancer, and CKD, is the reason why preclinical 
models are useful to identify regenerative mechanisms, but fail to translate these results into 
successfully human studies. In addition, ideally, an experimental model should demonstrate 
protective activity of therapy beyond 6 hours postinjury, because clinical AKI is not routinely 
identified until 1 or more days postinjury for the deficiency of appropriate predictive biomarkers to 
guide selection, timing, and monitoring of therapy in patients. Common functional markers such as 
serum creatinine and blood urea nitrogen are late or insensitive indicators of AKI and their 
measurement are even completely useless in differentiating AKI from CKD. In 2013, Sapphire 
study [102] reported the results of a prospective, observational, international investigation that 
identified two new predictive biomarkers: tissue inhibitor of metalloproteinase-2 (TIMP-2) and 
insulin-like growth factor-binding protein 7 (IGFBP7). These two novel urinary biomarkers seemed 
to be noteworthy because they exhibited a key role in kidney damage prediction. For this reason, 
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they recently received FDA approval to assess risk of AKI and prediction of subsequent CKD 
development. IGFBP7 and TIMP-2 are G1 cell cycle inhibitors, and their increased levels in urines 
occur during the very early phases of cellular stress. Since development of CKD after AKI is 
associated with cell cycle arrest of tubular epithelial cells, which upregulates profibrotic cytokine 
production, promoting a maladaptive repair [94], activation and deactivation of cell cycle arrest at 
critical clinical time points for a patient may also prove to be targets of therapeutic intervention in 
the future. For this reason, detection of urine TIMP-2 and IGFBP7 could be quite useful to 
recognize the moment to start the treatment in order to avoid progression of the injury. Thus, 
fostering tubular proliferation capacity may represents the critical aspect in order to obtain a shift 
toward renal regeneration instead of progression of a maladaptive response. 
In conclusion, efforts that concentrates on the potential regenerative capacity of the kidney will be 
advantageous when the experimental results are translated into clinical practice and they will open 
the way to new therapeutic strategies to halt the progression of CKD. 
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Article highlights Box 
• Glomerular regeneration is mainly driven by Renal Progenitors Cells (RPCs). 
• Cells of renine lineage (CoRL) were described as a putative source of parietal epithelial cells 
that, in turn, regenerate podocytes. 
• Targeting of several potential pathways may accelerate the regenerative response of RPCs 
through the modulation of their differentiation and proliferation.  
• Several drugs or biological mediators may potentially modulate RPC capacity to proliferate 
and differentiate into podocytes and may thus be used to enhance glomerular regeneration. 
• The existence of a hypothetical population of tubular progenitors has been described in 
human adult kidney. Further studies are needed to enhance our knowledge of tubular 
regenerative capacity and to establish the role of putative tubular progenitors in response to 
injury. 
• Targeting of several potential pathways may accelerate the regenerative response of tubular 
epithelial cells through maladaptive response inhibition. 
 
Explanatory box 
Kidney architecture: 
• The nephron is the basic structural and functional unit of the kidney; it is considerably 
similar across phyletic groups and it is generated in a highly conserved manner. In 
mammals, the number of nephrons is roughly proportional to the body mass. 
• Each nephron, consist of a glomerulus, qthe filtering unit, which is connected through a 
neck to a tubule, specialized for reabsorption and secretion.  
• The glomerulus is composed of a Bowman's capsule and a network (as a tuft) of capillaries.  
• The Bowman's capsule is composed of parietal epithelial cells and renal progenitor cells.  
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• The tubule is divided into a proximal tubule, Henle’s loop (thin descending limb, thin 
ascending limb and thick ascending limb) and a distal tubule that connects to an excretion 
unit. 
Critical cells of the nephron for the renal regeneration: 
• The podocytes represent one of the three components of the glomerular filtration barrier 
together with the fenestrated endothelial cell and the glomerular basement membrane 
(GBM). These cells have limited capacity to divide and they cannot restore glomerular 
architecture through cell division. For this reason, the replacement of these cells by an 
intrarenal glomerular progenitor is critical. 
• Tubular epithelial cells play a central role in renal physiology and are the cell types most 
sensitive to ischemic and nephrotoxic injury. The high regenerative capacity of these cells 
after kidney injury is in the last decade questioned because epidemiological studies 
document that even mild AKI episodes imply a substantial risk of CKD that progresses 
toward ESRD because of the occurrence of maladaptive repair processes. For this reason, a 
better knowledge of several potential pathways that may accelerate the regenerative 
response of tubular epithelial cells through maladaptive response inhibition is mandatory.  
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Figure legend: 
Figure 1: Pathways and drugs that regulate RPC differentiation and/or proliferation are potential 
therapeutic targets to enhance the glomerular regeneration. RPCs: renal progenitor cells; GSK3s: 
Glycogen synthase kinases 3-α and –β; IFN: Interferon; RA: Retinoic acid; AngII/AT1: 
Angiotensin (Ang) II receptor type 1, AT1 
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Figure 2: Pathways that are potential targets in order to promote tubular regeneration rather than 
progression of tubulointerstitial fibrosis. HIF: hypoxia-inducible factor; YAP: Yes-associated 
protein.  
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Table 1. Findings on glomerular regeneration.  
ACE-I: agiotensin-converting-enzyme inhibitors; ARB: angiotensin receptor blockers, RAAS-I: 
Renin-Angiotensin-Aldosterone System Inhibition; GSK3s: Glycogen synthase kinases 3-α and –β; 
RPCs: renal progenitor cells; CoRL: cells of renine lineage; PEC: parietal epithelial cell; IFN: 
Interferon. 
 DISEASE TREATMENT OBSERVATION REF 
   
   
 H
U
M
A
N
S 
Diabetic nephropathy Pancreas transplantation Amelioration of renal function and regression of glomerular and tubular lesions 10 
Chronic proteinuric 
nephropathies ACE-I 
Amelioration of renal function and reduction of 
proteinuria 12 
Chronic proteinuric 
nephropathy Multi-drug treatment Stabilization of renal function 14 
Diabetic nephropathy Pancreas transplantation Regression of tubulo-interstitial lesions 11 
Chronic proteinuric 
nephropathy Multi-drug treatment Stabilization of renal function 13 
Proliferative 
glomerulonephritis 
Angiotensin II type I 
receptor blockers Reduction of RPCs proliferation 53 
 
A
N
IM
A
L 
M
O
D
EL
S 
Hypertension ARB Normalization of renal function, normalization of pathologic damage 16 
5/6 nephrectomy ACE-I, ARB or both Regression of glomerulosclerosis 18 
Genetically-determined 
progressive renal injury ACE-I 
Reduction of glomerulosclerosis, increase in 
capillary tissue, stabilization of interstitial injury 15 
Spontaneous glomerular 
injury ACE-I 
Regression of functional and structural changes,  
increase in the number of glomerular podocytes and 
of parietal podocytes 
20 
Diabetic nephropathy Leptin 
Reversal of both functional and structural measures 
of advanced diabetic nephropathy. Increase in 
podocyte number  
17 
Diabetic nephropathy CXCL12 antagonist Increase of podocyte number 40 
Focal segmental 
glomerulosclerosis  Notch inhibitor Differentiation of RPCs into podocytes 41 
Collapsing focal segmental 
glomerulosclerosis  Notch inhibition 
Decrease of parietal epithelial cell lesions, 
worsening of proteinuria 42 
β-catenin-deficient mice Conditional β-catenin knock out 
Switch in lineage differentiation of PECs toward a 
podocyte-like cell fate 44 
Focal segmental 
glomerulosclerosis  GSK3s inhibitor 
Proteinuria remission with increased number of 
newly generated podocytes. 36 
Podocyte injury model Exogenous miR-30 Ameliorate proteinuria and podocyte injury  48 
Nephrotoxic nephritis miR-193a blocker Reduce crescent formation, decrease proteinuria 51 
Glomerular injury ACE-I Reduction of RPCs proliferation 52 
Crescentic 
Glomerulonephritis 
Angiotensin II type I 
receptor blockers  Reduction of RPCs proliferation 53 
Focal segmental 
glomerulosclerosis  RAAS-I Enhance the plasticity of CoRL  54 
Focal segmental 
glomerulosclerosis  Prednisone Increase of podocyte number 56 
Adriamycin–induced 
nephropathy IFN-β Suppression of PEC differentiation into podocyte 57 
Adriamycin–induced 
nephropathy IFN-α Reduction of PEC proliferation 57 
Focal segmental Retinoic Acid Increase of podocyte number, improve of renal 45 
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glomerulosclerosis function 
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